Literature DB >> 19164803

The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.

Boris Boyanovsky1, Melissa Zack, Kathy Forrest, Nancy R Webb.   

Abstract

OBJECTIVE: In vitro data indicate that human LDL modified by Group V secretory phospholipase A(2) (GV sPLA(2)) is proatherogenic. Consistent with this, gain and loss of function studies demonstrated that GV sPLA(2) promotes atherosclerosis in LDLR(-/-) mice. The current study investigates whether GV sPLA(2) promotes atherosclerotic processes in apoE(-/-) mice. METHODS AND
RESULTS: LDL (d=1.019 to 1.063) from apoE(-/-) and LDLR(-/-) mice fed chow or Western diet were hydrolyzed by GV sPLA(2). Phosphatidylcholine on LDL from LDLR(-/-) mice fed either a chow or Western diet was hydrolyzed to a greater extent (61.1+/-0.4% and 45.3+/-4.6%) than the corresponding fractions from apoE(-/-) mice (41.7+/-3.6% and 39.4+/-1.2%). ApoE(-/-) LDL induced macrophage foam cell formation in vitro without modification by GV sPLA(2), whereas hydrolysis of LDLR(-/-) LDL was a prerequisite for foam cell formation. In contrast to findings in LDLR(-/-) mice, GV sPLA(2) deficiency did not significantly reduce atherosclerosis in apoE(-/-) mice, although collagen content was significantly reduced in lesions of apoE(-/-) mice lacking GV sPLA(2).
CONCLUSIONS: The ability of GV sPLA(2) to promote atherosclerotic lipid deposition in apoE(-/-) and LDLR(-/-) mice may be related to its ability to increase the atherogenic potential of LDL from these mice as assessed in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164803      PMCID: PMC2782483          DOI: 10.1161/ATVBAHA.108.183038

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  35 in total

1.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice.

Authors:  M Febbraio; E A Podrez; J D Smith; D P Hajjar; S L Hazen; H F Hoff; K Sharma; R L Silverstein
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions.

Authors:  K Ishiguro; K Kadomatsu; T Kojima; H Muramatsu; S Tsuzuki; E Nakamura; K Kusugami; H Saito; T Muramatsu
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

3.  Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice.

Authors:  Victoria L King; Stephen J Szilvassy; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-03-01       Impact factor: 8.311

Review 4.  Phospholipase A(2) in vascular disease.

Authors:  E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal:  Circ Res       Date:  2001-08-17       Impact factor: 17.367

5.  Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice.

Authors:  Nancy R Webb; Meredith A Bostrom; Stephen J Szilvassy; Deneys R van der Westhuyzen; Alan Daugherty; Frederick C de Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

6.  Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin.

Authors:  Laurence Gesquiere; Wonhwa Cho; Papasani V Subbaiah
Journal:  Biochemistry       Date:  2002-04-16       Impact factor: 3.162

7.  Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.

Authors:  Kohji Hanasaki; Katsutoshi Yamada; Shigenori Yamamoto; Yoshikazu Ishimoto; Akihiko Saiga; Takashi Ono; Minoru Ikeda; Mitsuru Notoya; Shigeki Kamitani; Hitoshi Arita
Journal:  J Biol Chem       Date:  2002-05-20       Impact factor: 5.157

8.  Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL.

Authors:  Boris B Boyanovsky; Preetha Shridas; Michael Simons; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2008-12-03       Impact factor: 5.922

Review 9.  New phospholipase A(2) isozymes with a potential role in atherosclerosis.

Authors:  Makoto Murakami; Ichiro Kudo
Journal:  Curr Opin Lipidol       Date:  2003-10       Impact factor: 4.776

10.  Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.

Authors:  Christofer Flood; Maria Gustafsson; Robert E Pitas; Lorenzo Arnaboldi; Rosemary L Walzem; Jan Borén
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-01-15       Impact factor: 8.311

View more
  17 in total

1.  Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity.

Authors:  Papasani Venkata Subbaiah; Xian-Cheng Jiang; Natalia A Belikova; Buzulagu Aizezi; Zhi Hua Huang; Catherine A Reardon
Journal:  Biochim Biophys Acta       Date:  2012-02-18

2.  Group V secreted phospholipase A2 plays a protective role against aortic dissection.

Authors:  Kazuhiro Watanabe; Yoshitaka Taketomi; Yoshimi Miki; Kiyotaka Kugiyama; Makoto Murakami
Journal:  J Biol Chem       Date:  2020-06-01       Impact factor: 5.157

3.  Biallelic mutations in PLA2G5, encoding group V phospholipase A2, cause benign fleck retina.

Authors:  Panagiotis I Sergouniotis; Alice E Davidson; Donna S Mackay; Eva Lenassi; Zheng Li; Anthony G Robson; Xu Yang; Jaimie Hoh Kam; Timothy W Isaacs; Graham E Holder; Glen Jeffery; Jonathan A Beck; Anthony T Moore; Vincent Plagnol; Andrew R Webster
Journal:  Am J Hum Genet       Date:  2011-12-01       Impact factor: 11.025

4.  Group V phospholipase A2 in bone marrow-derived myeloid cells and bronchial epithelial cells promotes bacterial clearance after Escherichia coli pneumonia.

Authors:  Norbert Degousee; David J Kelvin; Gerd Geisslinger; David M Hwang; Eva Stefanski; Xing-Hua Wang; Ali Danesh; Carlo Angioni; Helmut Schmidt; Thomas F Lindsay; Michael H Gelb; James Bollinger; Christine Payré; Gérard Lambeau; Jonathan P Arm; Armand Keating; Barry B Rubin
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

5.  A new era of secreted phospholipase A₂.

Authors:  Makoto Murakami; Hiroyasu Sato; Yoshimi Miki; Kei Yamamoto; Yoshitaka Taketomi
Journal:  J Lipid Res       Date:  2015-03-24       Impact factor: 5.922

6.  Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines.

Authors:  Boris B Boyanovsky; Xia Li; Preetha Shridas; Manjula Sunkara; Andrew J Morris; Nancy R Webb
Journal:  Cytokine       Date:  2010-02-06       Impact factor: 3.861

7.  Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.

Authors:  Michael V Holmes; Holly J Exeter; Lasse Folkersen; Christopher P Nelson; Montse Guardiola; Jackie A Cooper; Reecha Sofat; S Matthijs Boekholdt; Kay-Tee Khaw; Ka-Wah Li; Andrew J P Smith; Ferdinand Van't Hooft; Per Eriksson; Anders Franco-Cereceda; Folkert W Asselbergs; Jolanda M A Boer; N Charlotte Onland-Moret; Marten Hofker; Jeanette Erdmann; Mika Kivimaki; Meena Kumari; Alex P Reiner; Brendan J Keating; Steve E Humphries; Aroon D Hingorani; Ziad Mallat; Nilesh J Samani; Philippa J Talmud
Journal:  Circ Cardiovasc Genet       Date:  2014-02-21

Review 8.  Harmful and protective roles of group V phospholipase A2: Current perspectives and future directions.

Authors:  Sachin K Samuchiwal; Barbara Balestrieri
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-10-08       Impact factor: 4.698

9.  A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis.

Authors:  Eric Boilard; Ying Lai; Katherine Larabee; Barbara Balestrieri; Farideh Ghomashchi; Daisuke Fujioka; Reuben Gobezie; Jonathan S Coblyn; Michael E Weinblatt; Elena M Massarotti; Thomas S Thornhill; Maziar Divangahi; Heinz Remold; Gérard Lambeau; Michael H Gelb; Jonathan P Arm; David M Lee
Journal:  EMBO Mol Med       Date:  2010-05       Impact factor: 12.137

Review 10.  Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics.

Authors:  Kei Yamamoto; Yuki Isogai; Hiroyasu Sato; Yoshitaka Taketomi; Makoto Murakami
Journal:  Anal Bioanal Chem       Date:  2011-03-29       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.